Trypanosoma

Trypanosoma spp. are divergent protozoan parasites that cause human African trypanosomiasis, Chagas disease, and animal trypanosomiasis^[1][2]. Their core biology centers on stage-specific adaptation between mammalian hosts and insect vectors, requiring changes in morphology, organelle positioning, surface biology, and gene expression^[2][3]. Mechanistically, kinetoplastids contain glycosomes that compartmentalize major glycolytic and pentose-phosphate enzymes, supporting energy and carbohydrate metabolism^[4]. cAMP signaling differs from mammalian pathways because trypanosomatids lack G-protein-coupled receptors, possess structurally different adenylyl cyclases, and express class 1 cyclic nucleotide phosphodiesterases PDEA-D^[5]. Compared with related isoforms, only T. brucei PDEB, expressed as PDEB1 and PDEB2, has been reported essential after ablation^[5]. Disease models use T. brucei to study bloodstream infection, tsetse-vector differentiation, antigenic variation, cytokinesis, and drug discovery^[2][3]. For experimental intervention, N-myristoyltransferase inhibition causes trypanosomatid cell death, compromises virulence, and cures T. brucei infection in rodents^[6]. Neuropeptides also kill T. brucei by disrupting lysosome integrity, redistributing glycolytic enzymes, and inducing autophagic-like cell death^[7].